A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

NCT00000822 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Ritonavir
BIOLOGICAL: gp160 Vaccine (Immuno-AG)
DRUG: Stavudine
DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]